Prediction of target genes for miR-140-5p in pulmonary arterial hypertension using bioinformatics methods

Fangwei Li1, Wenhua Shi1, Yixin Wan2

  • 1Department of Respiratory Medicine The First Affiliated Hospital of Xi'an Jiaotong University China.

FEBS Open Bio
|December 12, 2017
PubMed

Insights

MicroRNA (miR)-140-5p is reduced in pulmonary arterial hypertension (PAH). This study identified miR-140-5p targets and pathways, revealing its role in PAH pathogenesis and potential therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiovascular Research

Background:

  • MicroRNA (miR)-140-5p expression is decreased in pulmonary arterial hypertension (PAH) patients and animal models.
  • Understanding miR-140-5p targets is crucial for elucidating PAH mechanisms.

Purpose of the Study:

  • To identify downstream target genes and signaling pathways regulated by miR-140-5p in PAH.
  • To provide theoretical evidence for the role of miR-140-5p in PAH pathogenesis.

Main Methods:

  • Bioinformatics analysis to predict target genes and upstream transcription factors (TFs) of miR-140-5p.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
  • Literature review to validate predicted targets and pathways.

Main Results:

  • Predicted downstream targets of miR-140-5p are involved in biological regulation, signal transduction, and stem cell proliferation.
  • Key signaling pathways implicated include Notch, TGF-beta, PI3K/Akt, and Hippo.
  • Validated 23 target genes and seven signaling pathways inhibited by miR-140-5p, largely consistent with predictions.

Conclusions:

  • miR-140-5p plays a significant role in regulating key pathways implicated in PAH.
  • The identified targets and pathways offer potential avenues for therapeutic intervention in PAH.
  • Further in vivo and in vitro studies are needed to confirm remaining predicted targets.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
675
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
566